# A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma P

Source: https://onco.cc/trials/nct06496178/  
OnCo record `nct06496178` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Petosemtamab in head and neck squamous cell carcinoma, run by Merus B.V., active and no longer recruiting.

## Summary

A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2) is a phase 3 interventional study registered as NCT06496178 by Merus B.V., with 621 participants enrolled, started 2024-06-25 and due to reach its primary completion in 2028-02. Interventions recorded: Petosemtamab, Investigator's Choice, Investigator's Choice, Investigator's Choice. Conditions listed: Head and Neck Squamous Cell Carcinoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06496178
- Phase: 3
- Setting: A Phase 3 Open-label, Randomized Controlled Study to Evaluate the Efficacy and Safety of Petosemtamab Compared With Investigator's Choice Monotherapy Treatment in Previously Treated Patients With Incurable, Metastatic/Recurrent Head and Neck Squamous Cell Carcinoma
- Sponsor: Merus B.V.
- Enrolled: 621

## Sources

- ClinicalTrials.gov NCT06496178: https://clinicaltrials.gov/study/NCT06496178

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [Petosemtamab](https://onco.cc/drugs/petosemtamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct06496178.json